Role of STAT3 pathway in genitourinary tumors

The STAT3 is often dysregulated in genitourinary tumors. In prostate cancer, STAT3 activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial–mesenchymal transition. In addition, STAT3 promotes the progression from carcinoma in situ to invasive bla...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoni, Matteo, Conti, Alessandro, Piva, Francesco, Massari, Francesco, Ciccarese, Chiara, Burattini, Luciano, Cheng, Liang, Lopez-Beltran, Antonio, Scarpelli, Marina, Santini, Daniele, Tortora, Giampaolo, Cascinu, Stefano, Montironi, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137995/
https://www.ncbi.nlm.nih.gov/pubmed/28031890
http://dx.doi.org/10.4155/fso.15.13
Descripción
Sumario:The STAT3 is often dysregulated in genitourinary tumors. In prostate cancer, STAT3 activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial–mesenchymal transition. In addition, STAT3 promotes the progression from carcinoma in situ to invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF. STAT3 is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role of STAT3 in genitourinary tumors, thus describing its potential for future therapeutic strategies.

Ejemplares similares